Join thousands of book lovers
Sign up to our newsletter and receive discounts and inspiration for your next reading experience.
By signing up, you agree to our Privacy Policy.You can, at any time, unsubscribe from our newsletters.
Pharma M&A versus alliances and its underlying value drivers
- Are M&A or alliances the right therapy for an ailing pharmaceutical industry?- A capital market perspective
part of the Corporate Finance and Governance series
- Binding:
- Hardback
- Pages:
- 201
- Published:
- September 27, 2015
- Edition:
- Dimensions:
- 215x154x17 mm.
- Weight:
- 362 g.
Delivery:
2-3 weeks
Expected delivery: December 12, 2024
Description of Pharma M&A versus alliances and its underlying value drivers
This study analyzes 229 M&A and 120 in-licensing deals in the pharmaceutical industry. The author shows from a capital market perspective that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. Significant determinants of success for both strategies are derived.
User ratings of Pharma M&A versus alliances and its underlying value drivers
Rate this book
In order to rate this book you must be logged in.Others also bought..
Find similar books
The book Pharma M&A versus alliances and its underlying value drivers can be found in the following categories:
You can, at any time, unsubscribe from our newsletters.
© 2024 Tales
All packages are shipped from our warehouse in the UK.
Company address: Esromgade 15, 3. - 2200 - DK
Registered company number: DK43351621
